Upcoming events – Pivotal data readouts for Ardelyx and Rhythm will set the tone for next year
Both Ardelyx and Rhythm Pharmaceuticals are looking for phase III clinical wins to kick off filing discussions for pipeline leads.
Cymabay can’t buck the Nash disappointment trend
As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.
ADA 2019 – another gut punch for Lilly
Lilly is still trying to find a therapeutic window following gastrointestinal issues with its brightest pipeline hope, the GIP/GLP1 agonist tirzepatide.
ADA 2019 – a good start for Beta Bionics
The iLet system showed decent blood sugar control in its first trial, but the highly automated system is far from proven.
ADA 2019 – Provention claims success where Lilly failed
The company’s teplizumab delays development of type 1 diabetes, but Lilly’s failure with the same project nine years earlier casts a long shadow.
ADA 2019 – Rewind makes Lilly’s Trulicity look average
Less than emphatic cardiovascular outcomes data leave Lilly looking vulnerable to Novo Nordisk’s competing drugs.
VTV’s diabetes reinvention gains some ground
After crashing on a late-stage Alzheimer’s failure last year VTV Therapeutics has taken a small step forward in type 1 diabetes.
Rose-tinted glasses might not save Genkyotex
Genkyotex has dredged the data to find a glimmer of hope with GKT831 in primary biliary cholangitis, but cash is running short.
Boehringer pushes pipeline progress
The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.